Ursula Matulonis, M.D., professor of Medicine, Harvard Medical School, Medical Director of Gynecologic Oncology, Dana-Farber Cancer Institute, explains the benefits of PARP inhibitors for patients with ovarian cancer.
Latest Conference Articles
Advertisement
Elizabeth Swisher, M.D., discusses the ARIEL2 study, which proved that rucaparib may be a promising agent for patients with recurrent ovarian cancer.
Advertisement
Elizabeth Swisher, M.D., professor, Department of Medicine, Division of Medical Genetics, University of Washington School of Medicine, Breast and Ovarian Cancer Prevention Program, Seattle Cancer Care Alliance, discusses the side effects of rucaparib in the ARIEL2 trial, for patients with relapsed, platinum-sensitive high-grade ovarian carcinoma.
Advertisement
Advertisement
Trending on CURE
1
Trodelvy Plus Keytruda Upholds Quality of Life in TNBC
2
ADC Use Rapidly Growing in Metastatic Breast Cancer Treatment
3
Camrelizumab Combo Extends Survival in Metastatic Cervical Cancer
4
Cancer Vaccine Plus Keytruda Slow Advanced Melanoma Progression
5
